The Many Benefits of Exercise

The most empowering data in the entire field: the 0 → something jump matters more than the something → more jump. Unfit individuals carry roughly 2× the mortality risk of fit individuals at the same body weight (Gillen 2019). Going from sedentary to any regular movement is the single biggest reduction in risk medicine has to offer.

Practical move: ask one question — "What did you do for movement yesterday?" Then build the prescription up from whatever that is.

The international consensus: 150–300 minutes per week of moderate-intensity aerobic activity, plus two sessions per week of muscle-strengthening. Below 150 min/week is considered insufficient; above 300 min/week the dose-response continues but flattens.

Use this as the entry-level prescription. It's the lowest target with population-level evidence behind it.

6 days/week, 30–60 minutes per session. Mix moderate and vigorous intensity. Build to 60–65% of max HR initially, then 70–75% as fitness improves. Aim for 60+ minutes when possible.

This is more than the WHO floor — it's the dose Ratey argues is required to feel the neurochemistry consistently. For most patients, the WHO floor is the target; for patients chasing mood, cognition, or addiction-recovery benefits, Ratey's dose is the goal.

Steady-state cardio gives you cardiovascular and mood benefits. Complex-skill work — martial arts, dance, racquet sports, climbing — adds attention regulation, motor learning, and coordination gains that steady-state doesn't.

This is especially important for patients with ADHD or cognitive-aging concerns. Ratey: pre-class cardio plus complex skill is the strongest single combination in the attention literature.

Two sessions per week minimum. Compound lifts (squat, hinge, push, pull, carry), progressive load. For older patients, focus on lower-body strength and balance.

This is non-negotiable for anyone in a calorie deficit (dietary, surgical, or pharmacologic) or on a GLP-1. See the dedicated GLP-1 Era walkthrough for why.

For the patient who will only walk: Japanese Interval Walking Training (IWT). Alternate 3 minutes of fast walking with 3 minutes of slow walking, for 30 minutes total, 4 days per week.

Compared to steady-state walking, IWT delivers better cardiorespiratory fitness, lower BP, better glucose control, and higher aerobic capacity. Same time investment, substantially more return.

The walk is a delivery system for several other interventions: sunlight (vitamin D, circadian alignment), nature exposure (lower cortisol, attention restoration), reduced screen time, and a slower-paced visual cortex load that the indoor environment cannot match.

If a patient lives somewhere safe and walkable, get them outdoors. If they don't, work with what you have — a treadmill walk at moderate intensity still beats none.

When a patient is losing weight quickly — pharmacologically, surgically, or via aggressive dietary restriction — the default assumption should be that fat and lean tissue are both leaving. Plan for it from day one.

This is not unique to GLP-1s — any negative energy balance does this. But the speed and magnitude of GLP-1-induced loss makes the issue more pressing.

Two sessions per week minimum. Compound lifts, progressive load. Cohen et al. (Frontiers in Endocrinology, 2025): in a 500 kcal/day deficit, only the resistance-training arm gained fat-free mass during weight loss — +1.15 kg in men, +0.94 kg in women — while still losing the most fat.

Without resistance training during weight loss, body composition is left on the table — regardless of whether the deficit is dietary, surgical, or pharmacologic.

From the 2025 Joint Advisory (ACLM, ASN, OMA, The Obesity Society): adequate protein and strength training to preserve lean mass is priority #6 of 8 nutritional priorities for GLP-1 patients.

Aim for at least 1.2 g/kg/day, distributed across meals rather than loaded into one. Consultation with a registered dietitian or exercise physiologist is reasonable for higher-acuity patients.

Aerobic conditioning drives cardiorespiratory fitness, which drives all-cause mortality reduction independent of weight. A patient who loses 50 pounds on semaglutide but stays sedentary is still in the high-mortality quadrant of the fitness-vs-BMI grid.

The point of cardio in the GLP-1 era is not weight — it's fitness. Different target, same prescription.

The World Obesity Federation position statement (Obesity Reviews, April 2026): every GLP-1 patient should participate in a comprehensive treatment program, with physical activity — particularly resistance training — to minimize muscle mass loss.

This is no longer aspirational. It's a stated standard from the world's leading obesity body. Document the conversation; refer when needed.

A 2026 paper in Cell Reports Medicine (Hankir et al.) across four mouse studies and a 12-week human pilot found that weight loss with GLP-1s does not result in disproportionate muscle loss. Liver and fat are doing most of the shrinking. Handgrip and knee-extension strength held steady in the human pilot.

The clinical translation: counsel patients accurately — DEXA measures lean body mass (which includes liver and other organs), not skeletal muscle specifically. The number on the report can overstate the muscle problem. Don't drop the resistance training recommendation either way.

Exercise itself raises endogenous GLP-1 secretion by approximately 37% (per Loh, OMA 2026, citing 2025 data). The exact mechanism is still being worked out, but the implication is patient-facing and uncomfortable for the pharma narrative: the body has an endogenous GLP-1 lever, and exercise pulls it.

This doesn't replace exogenous therapy in patients who need it. But it does give the active patient an answer to the question "can I do anything that works similarly without the drug?"